Literature DB >> 62817

Modulation of the alternative complement pathways by beta 1 H globulin.

K Whaley, S Ruddy.   

Abstract

C3b inactivator accelerator (A-C3bINA) was isolated from human plasma. An antiserum produced against the purified protein gave a reaction of identity with beta 1 H, a well-documented contaminant of C3 preparations. Beta 1 H appears to be composed of a single polypeptide chain containing a significant quantity of carbohydrate, and having a sedimentation coefficient of 5.6 on analytical, and 6.4 on sucrose density gradient ultracentrifugation. Its mol wt based on SDS polyacrylamide gel electrophoresis and equilibrium sedimentation is approximately 150,000, whereas it elutes from Sephadex G200 with an apparent mol wt of 300,000, suggesting that beta 1 H is an asymmetric molecule. Beta 1 H potentiates the inactivation of C3b by C3b inactivator, binds to EAC43 to limit the formation of EAC43bB and EAC43bBP, and in contrast to C3b inactivator, it increases the rate of loss of hemolytic sites from EAC43bB and EAC43bBP. For the C3b inactivator-potentiating effect, beta 1 H and C3b inactivator must necessarily be simultaneously present. The kinetics of inactivation of C3b by C3b inactivator and beta 1 H are first order, suggesting that potentiation is not a multistep process. The mechanisms of binding to C3b and inhibition of the alternative pathway convertases C3bB and C3bBP are currently unknown.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 62817      PMCID: PMC2190448          DOI: 10.1084/jem.144.5.1147

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  22 in total

1.  A stoichiometric assay for the fourth component of complement in whole human serum using EAC'la-gp and functionally pure human second component.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1967-12       Impact factor: 5.422

2.  Complement metabolism in the seronegative arthritides.

Authors:  K Whaley; B Canesi; A Moseley; W Morrow; R Sturrock; W Mitchell; W C Dick
Journal:  Ann Rheum Dis       Date:  1974-11       Impact factor: 19.103

3.  Alternate complement pathway: factors involved in cobra venom factor (CoVF) activation of the third component of complement (C3).

Authors:  L G Hunsicker; S Ruddy; K F Austen
Journal:  J Immunol       Date:  1973-01       Impact factor: 5.422

4.  The stoichiometric measurement of the serum inhibition of the first component of complement by the inhibition of immune hemolysis.

Authors:  I Gigli; S Ruddy; K F Austen
Journal:  J Immunol       Date:  1968-06       Impact factor: 5.422

5.  A new complement inhibitor in guinea pig serum.

Authors:  H Okada; S Kawachi; K Nishioka
Journal:  Jpn J Exp Med       Date:  1969-10

6.  Complement dependent immune phagocytosis. I. Requirements for C'1, C'4, C'2, C'3.

Authors:  I Gigli; R A Nelson
Journal:  Exp Cell Res       Date:  1968-07       Impact factor: 3.905

7.  The reliability of molecular weight determinations by dodecyl sulfate-polyacrylamide gel electrophoresis.

Authors:  K Weber; M Osborn
Journal:  J Biol Chem       Date:  1969-08-25       Impact factor: 5.157

8.  C3b inactivator of man. 3. Further purification and production of antibody to C3b INA.

Authors:  S Ruddy; L G Hunsicker; K F Austen
Journal:  J Immunol       Date:  1972-03       Impact factor: 5.422

9.  C3b inactivator of man. II. Fragments produced by C3b inactivator cleavage of cell-bound or fluid phase C3b.

Authors:  S Ruddy; K F Austen
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

10.  Isolation and analysis of the mechanism of action of an inactivator of C4b in normal human serum.

Authors:  N R Cooper
Journal:  J Exp Med       Date:  1975-04-01       Impact factor: 14.307

View more
  214 in total

Review 1.  Complement deficiency.

Authors:  K M O'Neil
Journal:  Clin Rev Allergy Immunol       Date:  2000-10       Impact factor: 8.667

2.  Synthesis of factors D, B and P of the alternative pathway of complement activation, as well as of C3, by guinea-pig peritoneal macrophages in vitro.

Authors:  C Bentley; W Fries; V Brade
Journal:  Immunology       Date:  1978-12       Impact factor: 7.397

3.  Different regulation of factor H and FHL-1/reconectin by inflammatory mediators and expression of the two proteins in rheumatoid arthritis (RA).

Authors:  M A Friese; J Hellwage; T S Jokiranta; S Meri; H J Müller-Quernheim; H H Peter; H Eibel; P F Zipfel
Journal:  Clin Exp Immunol       Date:  2000-08       Impact factor: 4.330

4.  Adrenomedullin upregulates M2-muscarinic receptors in cardiomyocytes from P19 cell line.

Authors:  Sophie Buys; Fatima Smih; Atul Pathak; Pierre Philip-Couderc; Patrick Verwaerde; Jean-Louis Montastruc; Philippe Rouet; Jean-Michel Senard
Journal:  Br J Pharmacol       Date:  2003-07       Impact factor: 8.739

5.  Polymorphism and deficiency of human factor H-related proteins p39 and p37.

Authors:  E Feifel; W M Prodinger; M Mölgg; W Schwaeble; D Schönitzer; V Koistinen; R Misasi; M P Dierich
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

Review 6.  Complement control protein factor H: the good, the bad, and the inadequate.

Authors:  Viviana P Ferreira; Michael K Pangburn; Claudio Cortés
Journal:  Mol Immunol       Date:  2010-08       Impact factor: 4.407

7.  Membrane-associated complement factor H on lymphoblastoid cell lines Raji expresses a co-factor activity for the factor I-mediated cleavage of C3b.

Authors:  M J Demares
Journal:  Immunology       Date:  1989-08       Impact factor: 7.397

8.  Pig complement regulator factor H: molecular cloning and functional characterization.

Authors:  Guido A Hegasy; Ute Willhoeft; Sandra A Majno; Harald Seeberger; Peter F Zipfel; Jens Hellwage
Journal:  Immunogenetics       Date:  2003-09-27       Impact factor: 2.846

9.  Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells.

Authors:  Sarah E Sartain; Nancy A Turner; Joel L Moake
Journal:  J Biol Chem       Date:  2018-03-19       Impact factor: 5.157

10.  Induction of immune cytolysis: tumor-cell killing by complement is initiated by covalent complex of monoclonal antibody and stable C3/C5 convertase.

Authors:  C W Vogel; H J Müller-Eberhard
Journal:  Proc Natl Acad Sci U S A       Date:  1981-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.